Scientists at BellBrook Labs developed a TR-FRET based version of the company’s Transcreener AMP2/GMP2 Assay, a high throughput screening assay that can be used for hundreds of enzymes, among them targets for cancer, cardiovascular diseases and infectious diseases. TR-FRET is the most preferred detection mode for HTS, and the availability of the new Transcreener assay will provide an attractive solution for scientists seeking a robust, HTS-proven solution for phosphodiesterase assays, ligase assays, and related assays.
Madison, WI (PRWEB) April 21, 2012 -- BellBrook Labs announced the launch of a new Transcreener AMP2/GMP2 Assay with a TR-FRET (time resolved Forster resonance energy transfer) readout, for sensitive detection of hundreds of enzymes of potential therapeutic interest including ligases, synthetases, phosphodiesterases and sialyltransferases. These and related enzymes are being targeted for a diverse range of diseases, including cancer, cardiovascular disease and infectious diseases, and robust high throughput assays are critical for these efforts. ...
